SBH
SWTX

Segall Bryant & Hamill’s SpringWorks Therapeutics SWTX Stock Holding History

Segall Bryant & Hamill’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-244,566
Closed -$10.8M – 631
2025
Q1 		$10.8M Buy
244,566
+51,107
+26% +$2.35M 0.17% 204
2024
Q4 		$6.99M Buy
193,459
+58,522
+43% +$2.04M 0.1% 280
2024
Q3 		$4.32M Sell
134,937
-5,504
-4% -$206K 0.06% 352
2024
Q2 		$5.29M Buy
+140,441
New +$5.91M 0.09% 277

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Segall Bryant & Hamill's SWTX Position: Q2 2025 in Review

Segall Bryant & Hamill sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 244,566 shares — an estimated $10.8M sold.

Segall Bryant & Hamill first reported a position in SWTX in Q2 2024 and held it in 4 quarters. The position peaked at $10.8M in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Segall Bryant & Hamill reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Segall Bryant & Hamill sold 244,566 SpringWorks Therapeutics shares in Q2 2025, an estimated $10.8M.
  • Segall Bryant & Hamill first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 4 quarters.
  • Segall Bryant & Hamill's SpringWorks Therapeutics position peaked at $10.8M in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Segall Bryant & Hamill's 13F filing for Q2 2025, filed 12 Aug 2025.